EFPIA has announced the launch of the IMI2 research funding initiative, which will build upon the success of the Innovative Medicines Initiative (IMI) in a continued effort to bring innovative solutions to patients. IMI is a public-private partnership between the European Commission and EFPIA, which has also recently launched its 9th call for proposals. Under the new EU framework programme Horizon 2020, IMI2 will carry on the collaborative spirit of IMI by bringing together the pharmaceutical industry, European government, and health research partners and patients to advance scientific research and development for a healthy European society.
IMI2 is jointly funded by EFPIA and health research industry partners and the European Commission’s innovation investment package, which has announced its strategy to support public-private partnerships in EU-funded research.
IMI2 lists as its aims:
- To advance trends in personalised medicines
- To further R&D in areas of unmet medical need
- To address the regulatory context in hopes of speeding translation from research to innovation